Transarterial Chemoembolization Combined With Donafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World Clinical Study

    June 2024 in “ Journal of Clinical Oncology ”
    NULL AUTHOR_ID, NULL AUTHOR_ID, NULL AUTHOR_ID, Mengzhou Xue, NULL AUTHOR_ID, NULL AUTHOR_ID, Wenzhe Fan
    Image of study
    TLDR The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
    The study evaluated the efficacy and safety of combining transarterial chemoembolization (TACE) with Donafenib as a first-line treatment for unresectable hepatocellular carcinoma (uHCC) in 48 patients. The median progression-free survival (PFS) was 12.8 months, and the one-year overall survival (OS) rate was 87.5%. The objective response rate was 58.3%, with a disease control rate of 81.3%. Common treatment-related adverse events included elevated AST (75.0%), increased bilirubin (72.9%), and elevated ALT (54.2%). Grade 3 or 4 adverse events were observed in 46.9% of patients, but no Grade 5 events occurred. The combination therapy showed good efficacy and tolerability, suggesting its potential as a first-line treatment for Chinese uHCC patients.
    Discuss this study in the Community →